Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saby George

Showing results (31-40 of 93) with videos related to

Pageof 10
Sort By:
JCO Oncology Practice|January 6, 2025
Treatment Patterns and Costs Among Patients With Metastatic Renal Cell Carcinoma in the United States: A Real-World Study Using Integrated Claims and Clinical DataDaniel M Geynisman, Nathan R Hill, Lisa C Rosenblatt, et al.
Cancer Treatment Reviews|July 1, 2025
Systematic literature review of intravenous versus subcutaneous administration of oncology therapies: A clinical, economic and patient perspectiveSaby George, Maria T Bourlon, Michael J Overman, et al.
Investigational New Drugs|May 31, 2020
Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinomaBradley A McGregor, Michael Gordon, Ronan Flippot, et al.
Frontiers in Oncology|May 17, 2021
Case Report: Immune Checkpoint Inhibitor-Induced Exuberant Tumor Inflammation With Accelerated Clinical Deterioration in Metastatic Renal Cell CarcinomaDharmesh Gopalakrishnan, Rohit K Jain, Laurie Herbst, et al.
The Oncologist|May 6, 2021
The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint InhibitorsSaby George, Elizabeth J Bell, Ying Zheng, et al.
Clinical Genitourinary Cancer|August 8, 2017
Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal CarcinomaMadelon Q Wentink, Henk M W Verheul, Sumanta K Pal, et al.
Urology|October 16, 2013
Understanding avoidance, refusal, and abandonment of chemotherapy before and after cystectomy for bladder cancerShabnam Rehman, Alice Crane, Rakeeba Din, et al.
BJU International|October 16, 2016
Impact of suboptimal neoadjuvant chemotherapy on peri-operative outcomes and survival after robot-assisted radical cystectomy: a multicentre multinational studyNobuyuki Hinata, Ahmed Aly Hussein, Saby George, et al.
Clinical Genitourinary Cancer|October 29, 2015
Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder CarcinomaVenkata K Pokuri, Johar R Syed, Zhengyu Yang, et al.
Journal of Comparative Effectiveness Research|July 11, 2023
Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinomaSvenja Petersohn, Bradley McGregor, Sven L Klijn, et al.
Pageof 10

Showing results (31-40 of 93) with videos related to

Sort By:
Pageof 10
JCO Oncology Practice|January 6, 2025
Treatment Patterns and Costs Among Patients With Metastatic Renal Cell Carcinoma in the United States: A Real-World Study Using Integrated Claims and Clinical DataDaniel M Geynisman, Nathan R Hill, Lisa C Rosenblatt, et al.
Cancer Treatment Reviews|July 1, 2025
Systematic literature review of intravenous versus subcutaneous administration of oncology therapies: A clinical, economic and patient perspectiveSaby George, Maria T Bourlon, Michael J Overman, et al.
Investigational New Drugs|May 31, 2020
Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinomaBradley A McGregor, Michael Gordon, Ronan Flippot, et al.
Frontiers in Oncology|May 17, 2021
Case Report: Immune Checkpoint Inhibitor-Induced Exuberant Tumor Inflammation With Accelerated Clinical Deterioration in Metastatic Renal Cell CarcinomaDharmesh Gopalakrishnan, Rohit K Jain, Laurie Herbst, et al.
The Oncologist|May 6, 2021
The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint InhibitorsSaby George, Elizabeth J Bell, Ying Zheng, et al.
Clinical Genitourinary Cancer|August 8, 2017
Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal CarcinomaMadelon Q Wentink, Henk M W Verheul, Sumanta K Pal, et al.
Urology|October 16, 2013
Understanding avoidance, refusal, and abandonment of chemotherapy before and after cystectomy for bladder cancerShabnam Rehman, Alice Crane, Rakeeba Din, et al.
BJU International|October 16, 2016
Impact of suboptimal neoadjuvant chemotherapy on peri-operative outcomes and survival after robot-assisted radical cystectomy: a multicentre multinational studyNobuyuki Hinata, Ahmed Aly Hussein, Saby George, et al.
Clinical Genitourinary Cancer|October 29, 2015
Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder CarcinomaVenkata K Pokuri, Johar R Syed, Zhengyu Yang, et al.
Journal of Comparative Effectiveness Research|July 11, 2023
Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinomaSvenja Petersohn, Bradley McGregor, Sven L Klijn, et al.
Pageof 10